



IMPAACT Plenary Session
Monday, 18 June 2018
1:00 PM – 5:15 PM
Palladian Ballroom
Omni Shoreham Hotel

Start Time	Topic	Presenter
Moderators: Sharon Nachman, MD and James McIntyre, MD		
1:00	Welcome	James McIntyre, MD
1:05	State of the IMPAACT Network	Sharon Nachman, MD
1:35	Maternal Isoniazid Preventive Therapy for Tuberculosis (TB) Prevention in High Burden TB/HIV settings: Results of the IMPAACT P1078 Trial	Amita Gupta, MD
2:05	Precision Vaccines: Rationale for Early Life Immunization Against HIV	Ofer Levy, MD, PhD
2:35	NIAID: State of the Institute and Priorities for HIV/AIDS Research	Anthony Fauci, MD
3:15	Break	
Moderators: Grace Aldrovandi, MD and James McIntyre, MD		
3:45	Imaging the Dynamics and Localization of Immune Cells <i>in situ</i> – New Insights and Technologies Useful to the HIV Cure Community	Ronald Germain, MD, PhD
4:20	Optimizing the Impact of PEPFAR	Ambassador Deborah Birx, MD
5:00	Recognition Awards	Sharon Nachman, MD
5:15	Adjourn	



**IMPAACT Scientific Committee
Meeting Agendas**

Monday, 18 June 2018

Treatment..... 8:00 AM – 10:30 AM
Tuberculosis..... 9:30 AM – 12:30 PM

Tuesday, 19 June 2018

Prevention..... 8:00 AM – 9:45 AM
Complications & Co-Morbidities
and NIH Panel..... 10:00 AM – 12:30 PM
Cure..... 12:00 PM – 2:30 PM

Treatment Scientific Committee Meeting Monday, 18 June, 8:00 AM – 10:30 AM

Start Time	Topic	Presenter
8:00	Welcome and Overview of Treatment Scientific Agenda	Elaine Abrams and Ted Ruel
Update on Dolutegravir		
8:05	Overview of Recent Findings on Dolutegravir	Elaine Abrams
8:20	Implications of Recent DTG Findings for IMPAACT 2010/VESTED	Lameck Chinula
8:30	Panel Discussion: Clinical Implications and Community Perspectives	<i>Moderator:</i> Elaine Abrams <i>Panelists:</i> Linda Barlow-Mosha, Yuitiang Durier, Maximina Jokonya, Ted Ruel
9:00	Audience Q&A	All
Treatment Committee Scientific Updates		
9:10	P1026s, Focus on TAF: <i>Pharmacokinetic Properties of Antiretrovirals Therapy During Pregnancy</i>	Mark Mirochnick
9:20	P1093: <i>Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents</i>	Ted Ruel
9:30	P1101: <i>Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Infants and Children</i>	Paul Krogstad
9:40	P1106: <i>Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants</i>	Adrie Bekker
9:50	P1110: <i>A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk</i>	Diana Clarke
10:00	Updates on Treatment Studies Enrolling, Pending and In Development	Elaine Abrams and Ted Ruel
10:15	Closing remarks	Elaine Abrams and Ted Ruel
10:30	Adjourn	

Tuberculosis Scientific Committee Meeting Monday, 18 June, 9:30 AM – 12:30 PM

Start Time	Topic	Presenter
9:30	Welcome and Overview of Tuberculosis Scientific Agenda	Anneke Hesselings Amita Gupta
Tuberculosis Prevention and Treatment Study Updates		
<i>Pediatric Trials for Multidrug-Resistant Tuberculosis</i>		
9:45	<i>P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease</i>	Anneke Hesselings
9:50	<i>IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children with MDR-TB</i>	Ethel Weld
9:55	<i>IMPAACT 2020: Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-Center Trial</i>	Anthony Garcia-Prats
10:00	Drug Susceptible TB: Opportunities and Priorities	TB Scientific Committee

[continued on next page]

Tuberculosis Scientific Committee Meeting
Monday, 18 June, 9:30 AM – 12:30 PM (continued)

Lessons Learned and Future Directions for TB Pregnancy Trials		
10:20	Update and Way Forward for Phase I/II Maternal and Pediatric Prevention Studies: <ul style="list-style-type: none"> - P1078: <i>A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings</i> - A5279: <i>One month of Rifapentine/Isoniazid to Prevent TB in People with HIV: BRIEF-TB</i> 	Amita Gupta
10:30	IMPAACT 2001: <i>A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection</i>	Jyoti Mathad
10:35	P1026s: <i>Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy</i>	Jennifer Hughes
10:40	TB Pregnancy Registry	TB Scientific Committee
Future Opportunities and Priorities for the TB Scientific Committee		
11:00	Innovative Statistical Methods for Phase III Tuberculosis Trials in Children	Soyeon Kim
11:20	State of the Art: TB Drug Pharmacokinetics at the Site of Disease	Veronique Dartois
11:40	Regulatory Perspectives from the FDA on Priorities and Methods for TB Trials in Children and Pregnant Women	Lynne Yao
12:00	Roundtable Discussion: Future MDR-TB Trials	TB Scientific Committee
12:30	Adjourn	

Prevention Scientific Committee Meeting Tuesday, 19 June, 8:00 AM – 9:45 AM

Start Time	Topic	Presenter
8:00	Welcome and Overview of Prevention Scientific Agenda	Lynda Stranix-Chibanda
Prevention of Vertical Transmission of HIV		
8:10	PROMISE: Progress to Date, Plans for the Future, and Gaps Remaining for Perinatal HIV Prevention	Mary Glenn Fowler and Patricia Flynn
8:25	Immune Correlates of Protection Against Postnatal HIV-1 Transmission Among Highly-Active Antiretroviral-Treated Mothers in the PROMISE Study	Eliza Hompe
Immune Strategies for Prevention		
8:40	Use of Non-Human Primates in TB Vaccine Research	Shelby O'Connor
9:10	HIV Neutralizing Antibody Responses in HIV-Infected Children from IMPAACT Repository Samples (NWCS 607)	Giny Fouda
9:25	Study Update: IMPAACT P1112: <i>Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants</i>	Coleen Cunningham
9:40	Closing Remarks	Lynda Stranix-Chibanda
9:45	Adjourn	

Complications & Co-Morbidities Scientific Committee and NIH Panel Meeting

Tuesday, 19 June, 10:00 AM – 12:30 PM

Start Time	Topic	Presenter
10:00	Committee Overview and Welcome	Allison Agwu and Mark Abzug
Presentations		
10:05	Long-Term Outcomes in Perinatally-Infected Children Who Have Received ART Since Early in Life	Grace John-Stewart
10:35	Addressing Complications in Adults with HIV (The ACTG Experience)	E. Turner Overton
Panel: All Institutes In? Interest and Prioritization of Complications Among Pediatric, Adolescent, and Pregnant Individuals with HIV		
11:05	Panelists: – Emily Erbelding Division of Microbiology and Infectious Diseases – Robert Yarchoan National Cancer Institute (NCI) – Lis Caler National Heart, Lung, and Blood Institute (NHLBI) – Rohan Hazra National Institute of Child Health and Human Development (NICHD) – Pim Brouwers National Institute of Mental Health (NIMH)	Open Panel Discussion
12:30	Adjourn	

Cure Scientific Committee Meeting Tuesday, 19 June, 12:00 PM – 2:30 PM

Start Time	Topic	Presenter
12:00	HIV Cure Landscape for Pediatric Populations	Deborah Persaud
12:10	Protocol Updates: <ul style="list-style-type: none"> - IMPAACT P1115 - IMPAACT 2008 - IMPAACT 2015 - IMPAACT P1107 	Ellen Chadwick Betsy McFarland Ann Chahroudi Yvonne Bryson
12:50	Report from <i>Framework for Initiating Pediatric Studies of HIV Cure Interventions: Scientific Knowledge Gaps, Regulatory and Ethical Considerations</i>	Patrick Jean-Philippe Hans Spiegel Steven Mphonda
1:30	Combination Therapy with Broadly Neutralizing Antibodies: Safety and Virologic Outcomes	Marina Caskey
2:00	Discussion	All
2:30	Adjourn	



NIAID and NICHD Investigators and Site Staff Breakout Sessions
Tuesday, 19 June 2018
7:00 AM – 8:00 AM

NIAID Sites

Start Time	Topic	Presenter
7:00	Question and Answer Period	DAIDS Representatives, IMPAACT Network Leadership, and Site Investigators
8:00 AM	Adjourn	

NICHD Sites

Start Time	Topic	Presenter
7:00	<ul style="list-style-type: none"> • Welcome and Awards • Enrollment on IMPAACT and NICHD Studies • NICHD P1081 and NICHD P1091 • Remarks • Question and Answer 	Jennifer Bryant Jennifer Bryant Nahida Chakhtoura Rohan Hazra All
8:00 AM	Adjourn	

Day 1: Friday, 15 June 2018

Time	Session	Location
6:00 PM – 8:00 PM	Community Meet and Greet Reception	Empire Patio

Day 2: Saturday, 16 June 2018

Time	Session	Presenter	Location
7:00 AM – 8:00 AM	Breakfast		Diplomat Ballroom
8:00 AM - 10:00 AM	Welcome, Introductions, and Team Building Activity	Leslie Raneri Emanuelli Msuya	Diplomat Ballroom
10:00 AM – 10:15 AM	Break		
Youth Engagement Panel Moderator: Gloria Coon			
10:15 PM – 12:15 PM	Youth Engagement Panel	Silvia Negrini Maximina Jokonya Lamar Yarborough	Diplomat Ballroom
12:15 PM – 1:00 PM	Lunch		Diplomat Ballroom
Concurrent Capacity Building Sessions			
1:00 PM – 5:00 PM (Break: 3:00 PM-3:20 PM)	Session 1: How to Review a Protocol and Provide Feedback	Emanuelli Msuya Rhonda White	Empire Ballroom
	Session 2: Research Literacy <i>*Translation Services Provided*</i>	Marie Theunissen Leslie Raneri Joel Pagan-Lizardi	Diplomat Ballroom
5:00PM – 5:15 PM	Evaluation and Wrap Up	Leslie Raneri Emanuelli Msuya	Diplomat Ballroom

Day 3: Sunday, 17 June 2018

Time	Session	Presenter	Location
7:00 AM – 8:00 AM	Breakfast		Diplomat Ballroom
Concurrent Capacity Building Sessions			
8:00 AM – 12:00 PM (Break 10:00 AM - 10:20 AM)	Session 3: Cultural Humility: Affirming Gender Identity and Sexual Orientation. A Presentation of Training Modules Developed by the DAIDS Cross-Network Transgender Working Group	Brian Minalga Naiymah Sanchez	Empire Ballroom
	Session 4: Research Ethics <i>*Translation Services Provided*</i>	Yuitiang Durier Shonte Daniels Jonathan Lucas	Diplomat Ballroom
12:00 PM – 12:30 PM	Lunch		Diplomat Ballroom
12:30 PM – 1:30 PM	Site and CAB Engagement	Steve Mphonda Maggie Malola	Diplomat Ballroom
1:30 PM – 3:15 PM	State of the Network and Scientific Committee Updates	Sharon Nachman	Diplomat Ballroom
3:15 PM – 3:30 PM	Break		
3:30 PM – 4:00 PM	Evaluation and Certificates	ILG Members	Diplomat Ballroom
4:00 PM – 5:30 PM	Community Discussion of Dolutegravir	IMPAACT Study Management Team	Diplomat Ballroom

Day 4: Monday, 18 June 2018

IMPAACT General Sessions

Time	Session	Location
7:00 AM – 8:00 AM	Breakfast	Diplomat Ballroom
8:00 AM – 10:30 AM	Treatment Scientific Committee Meeting	Blue Room
9:30 AM – 12:30 PM	Tuberculosis Scientific Committee Meeting	Empire Ballroom
12:00 PM – 1:00 PM	Lunch	Diplomat Ballroom
1:00 PM – 5:00 PM	IMPAACT Plenary Session <i>*Translation Services Provided*</i>	Palladian Ballroom
7:00 PM – 10:00PM	IMPAACT Poster Session and Welcome Gathering	Empire Ballroom

Day 5: Tuesday, 19 June 2018

IMPAACT General Sessions

Time	Session	Location
6:30 AM – 8:30 AM	Breakfast	Palladium Foyer, Regency Foyer and Diplomat Foyer
8:00 AM – 10:30 AM	Prevention Scientific Committee Meeting	Palladian Ballroom
10:00 AM – 12:30 PM	Complications & Comorbidities Scientific Committee Meeting	Regency Ballroom
12:00 PM – 2:30 PM	Cure Scientific Committee Meeting <i>*Lunch Served Inside the Meeting Room*</i>	Diplomat Ballroom
3:00 PM – 6:00 PM	SLG & SC Chairs/Vice Chairs Meeting	Palladian Ballroom



Day 6: Wednesday, 20 June 2018

IMPAACT General Sessions

Time	Session	Location
8:00 AM – 10:00 AM	ACTG – IMPAACT: Training for Trauma Informed Care for Transgender Research Participants	Ambassador Ballroom
8:00 AM – 12:00 PM	Scientific Leadership Group Meeting	Executive Room